Oxycodone News and Research

RSS

Labopharm third quarter total revenue increases to $9.6 million

Labopharm Inc. today reported its financial results for the third quarter and first nine months ended September 30, 2010.

11 Nov 2010

Covidien fourth quarter net sales increase 3% to $2.67 billion

Covidien plc today reported results for the fourth quarter of fiscal 2010 (July - September 2010). Fourth-quarter net sales of $2.67 billion increased 3% from the $2.59 billion reported a year ago, with foreign exchange rate movement reducing the quarterly sales growth rate by approximately one percentage point.

9 Nov 2010

Pisgah Labs receives QTDP grant to accelerate abuse deterrent technology

Pisgah Labs, Inc., an innovative drug development and active ingredient manufacturer located in Western North Carolina, has received a substantial federal grant.

4 Nov 2010

More effective therapeutic exercises underutilized in treatment of chronic neck pain

Duke University and University of North Carolina (UNC) researchers report in the November issue of Arthritis Care & Research that narcotics and diagnostic testing are overused in treating chronic neck pain. Their findings indicate clinicians may overlook more effective treatments for neck pain, such as therapeutic exercise. According to reviews cited in the study, evidence to support the effectiveness of therapeutic exercise in treating chronic neck pain is good, yet only 53% of subjects were prescribed such exercise.

28 Oct 2010

Few legitimate opioid users are getting information to keep medications safe

For some people with ongoing or chronic pain, opioids (medications such as oxycodone or hydrocodone) can make the difference between disability and the ability to function at near-normal levels. For those with acute pain, such as pain after surgery or injury, sound pain management with opioids can speed healing and recovery.

19 Oct 2010

Intellipharmaceutics announces FDA acceptance to file ANDA for Protonix generic version

Intellipharmaceutics International Inc. today announced that the Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for a generic version of Protonix (delayed release pantoprazole sodium).

18 Oct 2010

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Nektar Therapeutics presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious side effects associated with traditional opioid therapies.

18 Oct 2010

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Nektar Therapeutics today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.

18 Oct 2010

Labopharm, Paladin Labs expand commercial relationship

Labopharm Inc. and Paladin Labs Inc. today announced they have expanded their commercial relationship through three licensing and distribution agreements under which Paladin will distribute two of Labopharm's products in certain jurisdictions.

14 Oct 2010

QRxPharma's A$14 million Placement oversubscribed

QRxPharma Limited has today announced a Placement which raised A$14 million and which was significantly oversubscribed.

1 Oct 2010

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic low back pain have been published online by Expert Opinion on Pharmacotherapy. In addition, this study compared oxycodone controlled-release (CR) to placebo as an active control.

28 Sep 2010

Opiate usage increases in workplace and ER

More American workers and job applicants are testing positive for prescription opiates, according to U.S. general workforce data in the 2009 annual Drug Testing Index™ (DTI) released today by Quest Diagnostics Incorporated, the nation's leading provider of diagnostic testing, information and services. Results from more than 5.5 million urine drug tests reveal an 18 percent jump in opiate positives in the general U.S. workforce in a single year (2008 to 2009), and a more than 40 percent climb from 2005 to 2009.

17 Sep 2010

Elite Pharmaceuticals signs agreements with Precision Dose for four generic products

Elite Pharmaceuticals, Inc. announced today the signing of a license agreement and a manufacturing and supply agreement with Precision Dose, Inc. which has a wholly owned subsidiary, TAGI Pharma, Inc. which will distribute the products covered by the agreement. Pursuant to the License Agreement, TAGI Pharma will market and sell four Elite generic products in the United States, Puerto Rico and Canada.

17 Sep 2010

QRxPharma announces interim analysis of MoxDuo IR clinical program

QRxPharma announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission.

2 Sep 2010

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation.

31 Aug 2010

Obama administration touts federal efforts to combat health care fraud

The Los Angeles Times: Obama administration officials at a meeting in Los Angeles Thursday touted their efforts to crack down on health care fraud, "saying quickly expanding criminal enterprises are costing taxpayers billions of dollars each year. ... Atty. Gen. Eric H. Holder Jr. and Health and Human Services Secretary Kathleen Sebelius said their agencies were jointly targeting fraud in the federal Medicare and Medicaid programs.

27 Aug 2010

USPTO grants Collegium second patent for tamper-resistant DETERx formulation platform

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that a new patent has been issued by the U.S. Patent and Trademark Office (USPTO) relating to its tamper-resistant DETERx™ formulation platform. US Patent Number 7,771,707 contains claims that cover Collegium's proprietary extended-release formulations, which are designed to resist dose dumping when subjected to a variety of physical methods of tampering.

18 Aug 2010

Oxycodone News and Research

Labopharm third quarter total revenue increases to $9.6 million

Covidien fourth quarter net sales increase 3% to $2.67 billion

Pisgah Labs receives QTDP grant to accelerate abuse deterrent technology

More effective therapeutic exercises underutilized in treatment of chronic neck pain

Few legitimate opioid users are getting information to keep medications safe

Intellipharmaceutics announces FDA acceptance to file ANDA for Protonix generic version

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Labopharm, Paladin Labs expand commercial relationship

QRxPharma's A$14 million Placement oversubscribed

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Opiate usage increases in workplace and ER

Elite Pharmaceuticals signs agreements with Precision Dose for four generic products

QRxPharma announces interim analysis of MoxDuo IR clinical program

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Obama administration touts federal efforts to combat health care fraud

USPTO grants Collegium second patent for tamper-resistant DETERx formulation platform

Pisgah Labs receives Notice of Allowance for new patent relating to thyroid hormone drugs

Elite Pharmaceuticals reports decrease in manufacturing revenue for fiscal first quarter

Labopharm second-quarter total revenue increases to $6.8 million

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News